Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.
Manish A. Shah, MD, director of the Gastrointestinal Oncology Program within the Division of Hematology and Medical Oncology and the Center for Advanced Digestive Care at Weill Cornell Medical College/ NewYork-Presbyterian Hospital, discusses the updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
The DESTINY-Gastric01 study was quite exciting, says Shah. This was a phase 2 study of the novel antibody-drug conjugate trastuzumab deruxtecan in HER2-positive gastric cancer. It was a 2:1 randomization where patients received either trastuzumab deruxtecan or physician’s choice of standard chemotherapy.
The overall response rate was 51.3% in patients who received trastuzumab deruxtecan and a significant improvement in overall survival, with a 12-month OS rate of 52.1%. The median overall survival in the trastuzumab deruxtecan arm was 12.5 months versus 8.4 months in the chemotherapy arm (HR, 0.59; 95% CI, 0.39-0.88; P = .0097).
Based on those findings, there is a lot of excitement about this drug and a global follow-up study is being conducted now, concludes Shah.